Inventor · disambiguated record
Peter Bruenker
Also filed as: BRUENKER PETER
35 granted patents·44 pending applications·698 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
79 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0697US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0797US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0897US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 0997US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 1097US9382323B2Multispecific antibodies comprising full length antibodies and single chain fab fragmentsBRINKMANN ULRICH·Filed 2010·Granted Jul 5, 2016·77 cites·22 claims
- 1197US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 1296US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 1396US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 1495US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 1595US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 1693US11242396B2Bispecific antigen binding molecules comprising anti-FAP clone 212HOFFMANN LA ROCHE·Filed 2019·Granted Feb 8, 2022·14 cites·36 claims
- 1791US11459404B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2017·Granted Oct 4, 2022·5 cites·1 claims
- 1891US10323099B2Multispecific domain exchanged common variable light chain antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 18, 2019·13 cites·12 claims
- 1990US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 2090US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 2188US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 2287US10087250B2Fc-free antibodies comprising two fab-fragments and methods of useROCHE GLYCART AG·Filed 2013·Granted Oct 2, 2018·10 cites·12 claims
- 2387US9481730B2DR5—FAP bispecific death receptor agonistic antibodiesBRUENKER PETER·Filed 2010·Granted Nov 1, 2016·29 cites·9 claims
- 2487US2025101135A1Antigen binding molecules comprising a tnf family ligand trimerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2586US11525007B2Antibody fab and Fc variantsHOFFMANN LA ROCHE·Filed 2018·Granted Dec 13, 2022·3 cites·5 claims
- 2686US2024425616A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 2784US2023340160A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2023·Application pending·0 cites
- 2880US12441812B2Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 2979US9975958B2Trimeric antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted May 22, 2018·3 cites·23 claims
- 3079US2022242971A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 3178US2025179205A1Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fapHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3277US12139553B2T cell activating bispecific antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Nov 12, 2024·0 cites·20 claims
- 3377US12103982B2T cell activating bispecific antigen binding moleculesHOFFMANN LA ROCHE·Filed 2021·Granted Oct 1, 2024·0 cites·14 claims
- 3476US8859234B2Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2013·Granted Oct 14, 2014·3 cites·37 claims
- 3576US8367374B2Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector functionROCHE GLYCART AG·Filed 2004·Granted Feb 5, 2013·9 cites·33 claims
- 3675US12202870B2Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereofHOFFMANN LA ROCHE·Filed 2021·Granted Jan 21, 2025·0 cites·40 claims
- 3775US2023119537A1Protease-activated t cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3873US12275794B2Bispecific antigen binding molecules comprising anti-FAP clone 212HOFFMANN LA ROCHE·Filed 2021·Granted Apr 15, 2025·0 cites·27 claims
- 3973US2022275087A1Protease-activated t cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4070US12240911B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2019·Granted Mar 4, 2025·0 cites·20 claims
- 4170US2023227584A1Bispecific antibodies comprising a modified c-terminal crossfab fragmentHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4270US2025320305A1Bispecific antigen binding molecules comprising anti-fap clone 212HOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 4368US2022073646A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4468US2022049020A1Tetravalent multispecific antibodiesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4567US12145994B2Bispecific antigen binding molecules capable of specific binding to CD40 and to fapHOFFMANN LA ROCHE·Filed 2021·Granted Nov 19, 2024·0 cites·17 claims
- 4667US2025092128A1Folr1 protease-activatable t cell bispecific antibodiesHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4767US2019322763A1Novel immunoconjugatesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 4866US2020172633A1Common light chains and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4966US2023123178A1Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moietyHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 5066US2020270321A1Antigen binding molecules comprising a trimeric tnf family ligandHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peter Bruenker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →